Abstract 237P
Background
Advanced urothelial cancer is an aggressive tumor type with high propensity of recurrence even after adequate surgical resection. The CheckMate-274 trial heralded a new era for resected urothelial cancer by the addition of adjuvant nivolumab which significantly reduced recurrence rate and prolonged survival. In the CheckMate-274 trial, 21% of the patients were upper urinary tract cancers (UTUC, including renal pelvis, collecting duct, ureter), reflecting the prevalence of UTUC in the western population. Asian patients have a significantly higher proportion of UTUC compared to western countries. Furthermore, in Asia, especially Taiwan, the etiology of urothelial cancers is likely distinct from western countries, with environmental factors as a main contributing factor. Therefore, the clinical efficacy of nivolumab in resected UTUC is relatively underinvestigated and warrants more research.
Methods
We retrospectively analyzed patients with resected urothelial cancer at the Taipei Veterans General Hospital, Taiwan, who received adjuvant nivolumab following adequate surgical resection. Clinical and pathological information were gathered and analyzed. We further collected genomic and clinical data for a further analysis of patients who had recurrence after completing adjuvant nivolumab.
Results
Our cohort included a total of 22 patients. 14 were female, 8 were male patients. 2 patients had bladder cancer, 4 patients had cancer of the ureter, and 16 patients had cancer of the renal pelvis (total of 20 UTUC). 3 patients were stage 2, 11 patients were stage 3, 8 patients were stage 4. With a median follow up time of 422.5 days, 7 patients had recurrence. In all 7 patients with recurrence, the median time to recurrence was 224 days (7.47 months). In the overall cohort, DFS was still not reached since the majority of patients were still in remission. We further performed genetic and pathological analysis for patients with recurrence.
Conclusions
Urothelial cancer is an aggressive disease with a dismal outcome. Adjuvant nivolumab significantly improved outcomes, but a portion of patients still present with rapid recurrence. Our study highlights the aggressiveness of UTUC which is highly prevalent in Asian countries.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract